Suppr超能文献

用于胚胎干细胞筛选和小鼠基因分型的等位基因缺失检测法。

The loss-of-allele assay for ES cell screening and mouse genotyping.

作者信息

Frendewey David, Chernomorsky Rostislav, Esau Lakeisha, Om Jinsop, Xue Yingzi, Murphy Andrew J, Yancopoulos George D, Valenzuela David M

机构信息

VelociGene Division, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.

出版信息

Methods Enzymol. 2010;476:295-307. doi: 10.1016/S0076-6879(10)76017-1.

Abstract

Targeting vectors used to create directed mutations in mouse embryonic stem (ES) cells consist, in their simplest form, of a gene for drug selection flanked by mouse genomic sequences, the so-called homology arms that promote site-directed homologous recombination between the vector and the target gene. The VelociGene method for the creation of targeted mutations in ES cells employs targeting vectors, called BACVecs, that are based on bacterial artificial chromosomes. Compared with conventional short targeting vectors, BacVecs provide two major advantages: (1) their much larger homology arms promote high targeting efficiencies without the need for isogenicity or negative selection strategies; and (2) they enable deletions and insertions of up to 100kb in a single targeting event, making possible gene-ablating definitive null alleles and other large-scale genomic modifications. Because of their large arm sizes, however, BACVecs do not permit screening by conventional assays, such as long-range PCR or Southern blotting, that link the inserted targeting vector to the targeted locus. To exploit the advantages of BACVecs for gene targeting, we inverted the conventional screening logic in developing the loss-of-allele (LOA) assay, which quantifies the number of copies of the native locus to which the mutation was directed. In a correctly targeted ES cell clone, the LOA assay detects one of the two native alleles (for genes not on the X or Y chromosome), the other allele being disrupted by the targeted modification. We apply the same principle in reverse as a gain-of-allele assay to quantify the copy number of the inserted targeting vector. The LOA assay reveals a correctly targeted clone as having lost one copy of the native target gene and gained one copy of the drug resistance gene or other inserted marker. The combination of these quantitative assays makes LOA genotyping unequivocal and amenable to automated scoring. We use the quantitative polymerase chain reaction (qPCR) as our method of allele quantification, but any method that can reliably distinguish the difference between one and two copies of the target gene can be used to develop an LOA assay. We have designed qPCR LOA assays for deletions, insertions, point mutations, domain swaps, conditional, and humanized alleles and have used the insert assays to quantify the copy number of random insertion BAC transgenics. Because of its quantitative precision, specificity, and compatibility with high throughput robotic operations, the LOA assay eliminates bottlenecks in ES cell screening and mouse genotyping and facilitates maximal speed and throughput for knockout mouse production.

摘要

用于在小鼠胚胎干细胞(ES细胞)中产生定向突变的靶向载体,其最简单的形式是由一个药物选择基因组成,两侧是小鼠基因组序列,即所谓的同源臂,它促进载体与靶基因之间的位点定向同源重组。用于在ES细胞中产生靶向突变的VelociGene方法采用基于细菌人工染色体的靶向载体,称为BACVecs。与传统的短靶向载体相比,BACVecs具有两个主要优点:(1)它们更长的同源臂可提高靶向效率,而无需同基因性或阴性选择策略;(2)它们能够在单个靶向事件中进行长达100kb的缺失和插入,从而有可能产生基因敲除的确定无效等位基因和其他大规模基因组修饰。然而,由于其臂长较大,BACVecs不允许通过传统检测方法(如长距离PCR或Southern印迹)进行筛选,这些方法将插入的靶向载体与靶向位点联系起来。为了利用BACVecs在基因靶向方面的优势,我们在开发等位基因缺失(LOA)检测方法时颠倒了传统的筛选逻辑,该方法可量化突变所针对的天然位点的拷贝数。在一个正确靶向的ES细胞克隆中,LOA检测可检测到两个天然等位基因中的一个(对于不在X或Y染色体上的基因),另一个等位基因则被靶向修饰破坏。我们以相反的方式应用相同的原理作为等位基因增加检测来量化插入的靶向载体的拷贝数。LOA检测显示,一个正确靶向的克隆失去了一个天然靶基因的拷贝,并获得了一个耐药基因或其他插入标记的拷贝。这些定量检测的组合使得LOA基因分型明确且适合自动评分。我们使用定量聚合酶链反应(qPCR)作为我们的等位基因定量方法,但任何能够可靠区分靶基因一个和两个拷贝之间差异的方法都可用于开发LOA检测。我们已经设计了用于缺失、插入、点突变、结构域交换、条件性和人源化等位基因的qPCR LOA检测,并使用插入检测来量化随机插入BAC转基因的拷贝数。由于其定量精度、特异性以及与高通量机器人操作的兼容性,LOA检测消除了ES细胞筛选和小鼠基因分型中的瓶颈,并为敲除小鼠的生产提供了最大速度和通量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验